How Investors May Respond To Kanzhun (BZ) Boosting Capital Returns With New Dividend Policy And Buyback Plan

Kanzhun Ltd. Sponsored ADR +1.02%

Kanzhun Ltd. Sponsored ADR

BZ

13.39

+1.02%

  • In March 2026, Kanzhun Limited reported fourth-quarter 2025 revenue of CNY 2,078.53 million and net income of CNY 694.18 million, alongside full-year revenue of CNY 8,267.52 million and net income of CNY 2,735.34 million, and announced new earnings guidance for the first quarter of 2026.
  • On the same day, Kanzhun’s board strengthened its capital return framework by introducing an annual dividend policy, committing to allocate at least half of adjusted net income to dividends and buybacks over the next three years, and increasing its share repurchase authorization to US$400 million through August 28, 2027.
  • We’ll now consider how Kanzhun’s commitment to returning at least half of adjusted net income to shareholders may reshape its investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Kanzhun Investment Narrative Recap

To own Kanzhun, you need to believe its AI driven recruitment platform can keep attracting both employers and job seekers despite demographic and competitive pressures. The new commitment to return at least half of adjusted net income to shareholders does not change the core product or user growth story, but it does sharpen focus on near term execution risk around cyclical hiring and monetization of lower tier and blue collar segments.

The most relevant update here is Kanzhun’s decision to allocate no less than 50% of adjusted net income to dividends and buybacks for the next three years. Coupled with higher 2025 earnings and the expanded US$400 million repurchase authorization through August 28, 2027, this ties the investment case more tightly to ongoing profitability and cash generation, making any slowdown in recruitment demand or rising acquisition costs more visible in shareholder returns.

Yet investors should also weigh how intensifying competition and rising AI automation could affect Kanzhun’s margins and long term earnings power...

Kanzhun's narrative projects CN¥11.2 billion revenue and CN¥3.7 billion earnings by 2028. This requires 13.2% yearly revenue growth and an earnings increase of about CN¥1.5 billion from CN¥2.2 billion today.

Uncover how Kanzhun's forecasts yield a $25.47 fair value, a 87% upside to its current price.

Exploring Other Perspectives

BZ 1-Year Stock Price Chart
BZ 1-Year Stock Price Chart

Some of the most optimistic analysts were assuming revenue near CN¥11.9 billion and earnings around CN¥4.4 billion by 2028, which is far more bullish than consensus and leans heavily on aggressive AI driven margin gains; with the new capital return plan and updated guidance, you now have fresh information that could either support or challenge that view, so it is worth comparing these different outlooks before deciding which narrative you find more convincing.

Explore 3 other fair value estimates on Kanzhun - why the stock might be worth just $21.04!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Kanzhun research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • Our free Kanzhun research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kanzhun's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

  • Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
  • Find 53 companies with promising cash flow potential yet trading below their fair value.
  • AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.